Ask AI
ProCE Banner Activity

TROP2-Directed ADCs for Unmet Needs in HR+/HER2- MBC and TNBC

Slideset

Review slide-based evidence on treatment attrition, limitations of conventional chemotherapy, and the rationale for TROP2-directed ADCs in HR-positive/HER2-negative metastatic breast cancer and TNBC.

Released: November 16, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This educational activity is intended for European oncologists and other healthcare professionals who care for patients with metastatic TNBC or HR+/HER2− MBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with HER2-negative MBC who may benefit from TROP-2-directed ADC therapy 

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content, generating clinical case(s) or scenario(s), and drafting assessment question(s) and/or rationale(s). All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.